Accessibility Menu
Via Pharmaceuticals logo

Via Pharmaceuticals(OTC) VIAP

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0%
+0.00Today
Via Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-05-06
Via Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002025-12-15
1 month+0%USD 0.002025-12-15
3 month+0%USD 0.002025-12-15
Year to date+0%USD 0.002025-12-15
1 year+0%USD 0.002025-04-24
3 year+0%USD 0.002023-05-01
5 year-99.99%USD 0.012021-05-03
Since inception-100%USD 7.752007-06-06

Via Pharmaceuticals Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.60M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1076.67 (Low)

Price

$0.00

Volume

6,800

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 26, 2025

VIAP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Via Pharmaceuticals

VIA Pharmaceuticals, Inc. is an emerging biotechnology company focused on developing therapeutic compounds for cardiovascular and metabolic disorders. The company aims to address critical health issues through a portfolio of small-molecule drug candidates.

Products and Services
  • VIA-3196: A THR beta agonist targeting dyslipidemia
  • DGAT1 inhibitor: In preclinical development for type 2 diabetes
  • VIA-2291: A 5-Lipoxygenase inhibitor for atherosclerotic plaque
Growth Outlook
  • Strong pipeline with multiple candidates in various development stages
  • Collaborations with Hoffman-LaRoche enhance research capabilities
  • Focus on addressing significant health issues presents market opportunities
Financial Highlights
  • Recent quarterly net income of -$2.47 million
  • Trailing twelve months (TTM) revenue of $0
  • Current ratio at 0.023, indicating liquidity challenges
VIA Pharmaceuticals is positioned in the healthcare sector, specifically within the medical and pharmaceutical industry. The company has made strides in developing innovative therapies aimed at significant health challenges, particularly in cardiovascular and metabolic disorders. The ongoing research and development efforts, along with strategic partnerships, are expected to bolster the company's growth trajectory. Despite facing financial challenges, including a recent quarterly net income loss, the company maintains a focus on advancing its drug candidates. The lack of revenue highlights the early-stage nature of the business, which is common in biotechnology firms. Investors may find the potential for future growth appealing, especially given the company's commitment to addressing critical health issues through its innovative product pipeline.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Headquarters

San Francisco, CA 94111, US

VIAP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

64.66%

Return on Capital

N/A

Return on Assets

-1920.37%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

20.56M

Volume

6.80K

Avg. Volume

140.323

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$6.02M

EBITDA

-$5.84M

Operating Cash Flow

-$6.11M

Capital Expenditure

$0.00

Free Cash Flow

-$6.11M

Cash & ST Invst.

$84.00K

Total Debt

$14.00M

Via Pharmaceuticals Performance Analysis

Via Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12010-03-31N/A
Q22010-06-30N/A
Q32010-09-30N/A
Q42010-12-31N/A
Via Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12010-03-3133.8%
Q22010-06-3021.4%
Q32010-09-309.1%
Q42010-12-31-20.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2010YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

6

N/A

Net Income

-$2.47M

+41.8%

EBITDA

-$876.99K

+68.5%

Quarterly Fundamentals

Name
Q4 2010YOY CHG

Total Cash

$84.00K

-96.2%

Total Debt

$14.00M

+40.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$14.00M

+40.1%

Return on Assets

-19.20%

N/A

Return on Invested Capital

32.56%

N/A

Free Cash Flow

-$1.19M

+50.3%

Operating Cash Flow

-$1.19M

+50.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OLMMOneLife Technologies Corp.
$0.00+0.00%
LFPILifePoint, Inc.
$0.00+0.00%
TRVNTrevena, Inc.
$0.01+0.00%
ICCTiCoreConnect Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About VIAP

What is the current price of Via Pharmaceuticals?

Via Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Via Pharmaceuticals?

Over the past 52 weeks, Via Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does Via Pharmaceuticals have?

Via Pharmaceuticals total debt is unavailable.

How much cash does Via Pharmaceuticals have on hand?

Via Pharmaceuticals does not have cash on hand data available.

What is Via Pharmaceuticals’s dividend yield?

Via Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.